In a crossover trial in 60 participants, the oxytocin receptor antagonist atosiban did not provoke more migraine-like attacks than placebo in women with episodic migraine (30% vs 20%, P=0.75); no difference was seen in men with migraine either.
RCTn = 60
Fitzek et al. Oxytocin receptor antagonism in migraine: a randomized, double-blind, placebo-controlled provocation study